

# Corporate Update

March 2020

CSE:MPXI  
OTCQX:MPXOF





## FORWARD LOOKING STATEMENTS

Certain statements contained in this presentation constitute forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and United States securities laws. Such forward-looking statements relate to future events or the future performance of MPXI International Corporation ("MPXI"). All statements other than statements of historical fact contained in this presentation may be forward-looking statements. The forward-looking statements contained in this document are based on certain key expectations and assumptions made by management of MPXI. Although management of MPXI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because MPXI can give no assurance that they will prove to be correct.

Certain statements in this presentation including, but not limited to, (i) statements that may contain words such as "expected", "will", "future", "developing", "grow", and similar expressions, including the negatives thereof or other comparable terminology; (ii) statements that are based on current expectations and estimates about the markets in which MPXI operates; and (iii) statements of belief, intentions, and expectations about developments, results, and events that will or may occur in the future, constitute forward-looking statements which are based on certain assumptions and analysis made by management of MPXI. Some of the assumptions which management of MPXI has made and which underlie the forward-looking statements include MPXI's future operational and production capacity, the impact of enhanced infrastructure and production capabilities, the impact of governmental laws and regulations and future growth. Forward-looking statements include, but are not limited to, statements with respect to development trends within the medical and adult use marijuana sectors, governmental laws and regulations, business strategy; expansion and growth of MPXI's business and operations; and other such matters. Such forward-looking statements are subject to material risk factors and uncertainties, many of which are beyond the control of MPXI, including, but not limited to, the MPXI's future operational and production capacity, the impact of enhanced infrastructure and production capabilities, the impact of governmental laws and regulations and future growth. The realization of risks is difficult to predict and may affect MPXI operations causing actual results to differ materially from forward-looking statements. Such material risk factors include, but are not limited to: the impact of general economic conditions; industry conditions; arising claims; partner events; operational opportunities; changing technology; government and regulatory developments; competition; the ability to obtain further financing and the ability of MPXI to attract and retain qualified personnel. These factors are not intended to represent a complete list of the general or specific factors that could affect MPXI. Further details on key risks can be found in MPXI's disclosure documents filed with securities regulators and available at [www.sedar.com](http://www.sedar.com), including its audited annual consolidated financial statements for the financial years ended September 30, 2019 and 2018 and the corresponding annual management's discussion and analysis.

MPXI's actual results, performance, or achievements could vary from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do transpire or occur, what benefits MPXI will derive therefrom. All forward-looking statements contained in this presentation represent the views of MPXI's management only as of the date of this presentation and should not be relied upon as representing the views of MPXI's management as of any date subsequent to the date of this presentation. Subject to applicable law, MPXI disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

All forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Unless otherwise indicated herein, references to "\$" or "CDN\$" are to Canadian dollars and references to "US\$" or "U.S. dollars" are to United States dollars.



Seasoned executive team with **proven experience building a successful U.S. business**, replicating it on a global scale



**Vertically integrated** distribution models and global supply chain to drive performance



Recent milestones in Canada, Europe and Australia reflect **increasing momentum in execution of strategic growth plan**



Established global footprint with **presence in six markets**, including Canada



**Proven formulations and brands** to “lift and place” into new geographies



Diversified asset base, **targeting medical, health and wellness and recreational channels**



# US STRATEGIC ACHIEVEMENTS



**\$835m**

Successful Exit from U.S. Asset  
Base in February 2019



**225**

Employees



Licensed for **6**  
Cultivation Facilities  
in Five Markets



Licensed for **15**  
Dispensaries in Five States



**\$100m**

Revenue Run Rate 2018



**\$135m+**  
Debt & Equity Raised

**WE BUILT AND SOLD A SUCCESSFUL BUSINESS FOR \$835M**

## Strategic Achievements



**6**

Countries in which MPXI is Operating



**12,000 sq. ft.**

Licensed Indoor Cultivation Canopy at Canveda Facility in Peterborough, Ontario



**2**

Retail Locations in London, UK and Geneva, Switzerland



**1 Million+**

BBC News readers on report of MPXI-featured documentary



**~90,000 kg**

Swiss Organic, High-CBD Biomass From 2019 Harvest



**20%+**

CBD present in Swiss Genetics



**\$26.9m**

Raised in Non-Brokered Private Placement




**3**

Industrial-Grade Extraction Labs in Development



# MPX BIOCEUTICAL TIMELINE: PRIOR NORTH AMERICAN CANNABIS STRATEGY





# MPX INTERNATIONAL TIMELINE: CURRENT INTERNATIONAL CANNABIS & CBD STRATEGY

MPX Biocetical sold to iAnthus for CDN\$835m. MPXI Maintains all Non-U.S. assets  
*(February 2019)*

Acquisition of Swiss Organic CBD-brand and outdoor cultivators Holyweed for CDN\$13.4m. Annual run rate must reach CHF 5m to meet terms  
*(May 2019)*

MPX Australia becomes a wholly-owned subsidiary with acquisition of remaining 49% for CDN\$4.0 million in MPXI shares upon meeting production milestones  
*(July 2019)*

Launch of “beleaf” Premium CBD retail experience in the UK located in the heart of the Soho District of central London  
*(November 2019)*

Accelerated acquisition of remaining 80% of KAAJENGA Cannabis for CDN\$1.75m acquiring control of Medical Cannabis Learning Network, a video learning and engagement platform.  
*(December 2019)*

Completed Definitive Agreements to Acquire 80% of First Growth for Joint Venture cannabis cultivation project in South Africa  
*(February 2020)*

*(March 2019)*  
Oversubscribed private placement US\$20m closes: Increased from initial US\$15m due to demand

*(August 2019)*  
Acquisition of MPXI Malta Property Ltd. for CDN\$2.3m. Received a LOI from the Economic Development Agency of Malta and member of EU for a License to Import, Extract, Produce and Distribute Cannabis.


*(November 2019)*  
MPX Australia Awarded Cannabis Manufacture License from the Australian Office of Drug Control

*(January 2019)*  
MPX Australia Awarded Medical Cannabis License from the Australian Office of Drug Control

*(February 2020)*  
Launch of Premium CBD Flagship Retail Store in Geneva located on one of Geneva’s busiest streets, Rue des Eaux-Vives, near the famed water fountain “Jet d’Eau”



# MPXI CORPORATE ORGANIZATION CHART



JURISDICTION
Australia
Canada
Malta
Ontario
Switzerland
United Kingdom
South Africa

\* Material Subsidiaries



# VERTICALLY INTEGRATED STRATEGY

## Cultivation

A light gray rounded rectangle containing logos for the cultivation stage. At the top is the MPXX International Corporation logo. Below it is the text 'FIRST GROWTH' next to a small graphic of three colored dots (green, yellow, and blue). At the bottom is the MPXX Australia logo.

**MPXX**  
INTERNATIONAL CORPORATION

FIRST GROWTH

**MPXX**  
AUSTRALIA


## Extraction & Manufacturing

A light gray rounded rectangle containing logos for the extraction and manufacturing stage. It features the MPXI Malta logo at the top and the MPXI Labs logo at the bottom.

**MPXI**  
MALTA

**MPXI**  
LABS

## Branding & Distribution

A light gray rounded rectangle containing logos for branding and distribution. It features the Holy Weed logo on the left, a small teal square icon in the center, and the Beleaf logo on the right.

**HOLY WEED**

beleaf

DRIVING PERFORMANCE FROM SEED TO SALE



**LEVERAGING EXPERTISE FROM SUCCESSFUL OPERATIONS IN THE U.S. TO CREATE FIRST MOVER ADVANTAGES**

# EUROPEAN OPERATIONS



Leading lifestyle brand supplying premium, organic Swiss CBD products



Swiss extraction laboratory in development, supplying custom cannabinoid formulations to brands globally



Received LOI from Malta Enterprise and developing GMP-ready manufacturing/packaging facility



UK's first LP owned CBD retail store in London with distribution of HolyWeed and beleaf branded-products through both retail and e-commerce channels

**STRONG BRAND AWARENESS PERMEATING ACROSS EUROPE**

# HOLY WEED



## Swiss-Made Product Line

- Pre-rolled joints of varying strengths
- Organic CBD oil
- Mood-specific CBD flower
- CBD infused Swiss Chocolate cookies
- Available on-line and at our Geneva dispensary
- Coming soon:
  - Additions to mood-specific strains
  - Vaporizer pens





## Swiss Extraction & Formulation Lab

- Swiss GMP Extraction and Formulation Lab in Development
- B2B Products Include:
  - Organic Certified Extracts under 1% THC
  - Custom Edible Formulations
  - Cosmetic Formulations

## EU-Based Medical Cannabis Processing

- Approval of LOI by Malta Enterprise
- GMP-ready manufacturing/packaging facility in development
- Once completed, the facility will enable the formulation and packaging of pharmaceutical-grade finished products for EU distribution of Salus BioPharma branded products



**LEADING EXTRACTION AND FORMULATION**

## Flagship CBD Dispensary in London's Soho District


**beleaf**  
Confidence in Cannabis

### Product Line

- Organic CBD extracts
- Disposable vaporizers
- Organic tinctures
- Plant-based cosmetics
- CBD-infused pressed juices

### Merchandise

- Hemp-based
- Organically sustainable
- High-quality branded clothing
- Accessories





- bQb-GMP-certified cultivation facility with 1,200 kg annual capacity
- Developing to EU-GMP Standards
- Installation of cutting-edge **tissue culture** laboratory



- 20,000 sq. ft. facility in development
- Will include production of high value cannabinoid-based medical products



SPARTAN  
WELLNESS

Supporting the Cannabis needs of Veterans and First Responders



MEDICAL CANNABIS  
LEARNING NETWORK

Kiosks located in clinics and pharmacies, to drive patient engagement and product purchases through a private on-line portal

Cultivation & Processing

Distribution



# MEDICAL CANNABIS LEARNING NETWORK



Direct consumer contact channel assists Canveda with patient acquisition



Proprietary card activation technology enables patients to access private network



Direct patient contact helps educate consumers, increase brand awareness



## DATA-DRIVEN SALES & EDUCATION PLATFORM

## Overview:

- **Approval of Cannabis Manufacture Licence** by Australia's Office of Drug Control
- Developing **EU-GMP processing facility**
- Installation of cutting-edge **tissue culture** laboratory
- Provides gateway to **Asian and Oceania** markets



**20,000 sq. ft.**

**Licensed Indoor Cultivation – in development**



**1**

**Industrial-Grade Extraction Lab – in development**




**Access to Asian & Oceania Markets**



## Overview:

- First Growth, **Joint Venture** owned 80% by MPXI and 20% by Simonsberg Cannabis, whose shareholders include Backsberg Estate Wineries
- Late-stage cultivation **application in process**
- Hi-tech greenhouse construction progressing rapidly
- Building to EU-GACP standards for **global export**





# MANAGEMENT TEAM

## W. SCOTT BOYES

**Chairman, President, Chief Executive Officer  
and Director**

- Former founder and CEO of MPX Bioceutical
- Senior executive with 35 years of diversified and cross-functional experience in banking, finance, transportation and general management
- Bachelor's Degree from The University of Western Ontario and an MBA from Rotman School of Management, University of Toronto

## JEREMY BUDD

**Executive VP, General Counsel, Corporate  
Secretary and Director**

- General Counsel through MPX Bioceutical growth and \$835 million sale in 2019
- Led 14 cannabis industry acquisitions in US, Canada and Europe, while successfully raising over \$160 million of debt and equity
- J.D./M.B.A. from Osgoode Hall Law School and Schulich School of Business at York University

## DAVID MCLAREN

**Chief Financial Officer**

- CFO of MPX Bioceutical through \$835 million sale in 2019
- Over 25 years of financial experience, with 10 years at CFO level with several consumer and industrial companies
- Chartered Professional Accountant and holds an Honours B. Com. degree from McMaster University

## MICHAEL ANRKVARN

**Chief Operating Officer, Canada**

- Managed Canadian operations and development at MPX Bioceutical
- Extensive management background in the operation of small-to-medium businesses since his graduation from McGill University in 1977 with a B.Sc. in Agricultural Sciences

## DANIEL FRYER

**Managing Director, Europe**

- Oversees MPXI's European operations and expansion initiatives
- Worked in business development for leading California brand, Moxie in 2016 and founded European advisory firm, Cannatlantic
- Analyst at J. P. Morgan, Bachelor's Degree from the Marshall School of Business at USC

## AMER CHEEMA, PH.D.

**Vice President, Cultivation**

- Oversees MPXI's cultivation facilities
- Ph.D. in Plant Physiology & Biochemistry from the University of Guelph, specializing in Phospholipase D inhibition technologies
- Previously Director of Cultivation at Goldleaf Pharm and as Head Grower at The Green Organic Dutchman



# BOARD OF DIRECTORS AND ADVISORY BOARD

## Board of Directors

### W. SCOTT BOYES

Chairman, President, Chief Executive Officer and Director

### JEREMY BUDD

Executive VP, General Counsel, Corporate Secretary and Director

### ROBERT PETCH

- Former Director of MPX Bioceutical
- 30+ years management, strategic planning, financial analysis experience
- Chartered Accountant, Hon. In Engineering Science from Oxford University

### RANDALL G. STAFFORD

- Former Director of MPX Bioceutical
- Former VP of Finance at Cushman & Wakefield (Canada) Inc.
- CPA, MBA from the Rotman School of Business at the University of Toronto

### ALASTAIR CRAWFORD

- 20+ years management, operations and strategic planning experience
- Founded and built a number of successful technology ventures since 1996
- Educated at the Harrow School (London)

## Advisory Board

### JEAN-MARC LEVY

- Former Global CMO, British American Tobacco
- Ex Director of Reynolds-American Inc prior to its acquisition by British American Tobacco

### DAMIAN WEST

- Strategic guidance for MPXI's African expansion initiatives
- Previously served as director on numerous boards and was Legislative Assistant to the Senate Foreign Relations Committee in Washington D.C.

### DR. CHARLES AKLE

- Leading world authority in the fields of cancer treatment, immunology
- Renowned for 30+ years as a pioneer in clinical surgery and biotech
- Guides MPXI's medical product development, market entry initiatives

### MILES THOMPSON PH.D.

- Former Director of MPX Bioceutical
- Ph.D. in Pharmacology from the University of Toronto
- Currently works in the Department of Pediatrics at UC San Diego



# PROJECTED MARKET VALUES FOR REVENUE SOURCES

(US\$ in millions)	End Market	Revenue Start Date	Projected Market Values			
			2020	2021	2022	2023
<b>Canada</b>	Canadian Legal Cannabis	Q1 2020	3,040	3,800	4,788	5,548
<b>Malta/South Africa</b>	European Legal Cannabis	Q3 2020	1,216	1,972	2,573	3,227
<b>Holy Weed/MPXI Labs</b>	European CBD	Q1 2020	610	920	1,330	1,670
<b>Australia</b>	Australian Legal Cannabis	Q4 2020	123	143	193	245
<b>Total</b>			<b>4,989</b>	<b>6,835</b>	<b>8,884</b>	<b>10,690</b>

Source: Prohibition Partners, Arcview Market Research, Brightfield Group, A.G.P. Research Reports

- Experienced management team that has successfully built and operated multiple businesses in the North American cannabis sector
- Large, sophisticated, international investor base
- Vertically-integrated on a global scale
- Strategic supply chain of low-cost biomass to high value markets
- Early-mover in high-potential growth markets
- Focus on higher-margin medical products
- Geographically diversified to reduce sovereign and regulatory risk

Corporate Website:

<http://mpxinternationalcorp.com>

MPXI Investor Learning Network:

<http://MPXI.TV>

[info@mpxinternationalcorp.com](mailto:info@mpxinternationalcorp.com)

CSE:MPXI  
OTCQX:MPXOF

